Abstract
Patients with intracranial hemorrhage (ICH) who are also on antiplatelet agents have an increased morbidity and mortality rate. Current international guidelines recommend considering a one-time dose of desmopressin (DDAVP) in patients with antiplatelet associated ICH (AA-ICH), however this recommendation is based on observational data suggesting DDAVP improves platelet function. There is limited data on the efficacy, as well as the safety, of DDAVP in AA-ICH.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
